Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Opexa Pharmaceuticals Inc., PharmaFrontiers deal

PFTR will acquire Opexa for 2.5 million shares

Read the full 89 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE